锂对胃排空及口服氯丙嗪吸收的影响。

Effect of lithium on gastric emptying and absorption of oral chlorpromazine.

作者信息

Rivera-Calimlim L

出版信息

Psychopharmacol Commun. 1976;2(3):263-72.

Abstract

A recent study suggested that low plasma levels (58-70 ng/ml) of chlorpromazine (CPZ) were achieved by patients concurrently taking lithium, despite ingestion of doses of CPZ (400-1000 MG) which ordinarily produce plasma levels of 100-300 ng/ml or more. We have studied this lithium-chlorpromazine interaction in rats. The plasma and brain levels of [14C]chlorpromazine (CPZ) after an oral dose (5 muCi) were significantly lower (p less than 0.005) in rats treated with lithium, whereas the percent of dose remaining in the stomach (24-30%) was significantly higher (p less than 0.001), than in matched controls. Gastric emptying was measured by [14C]polyethylene glycol and was shown to be inhibited significantly by oral and i.p. lithium. This inhibition of gastric emptying by lithium may be the major cause of the lower plasma levels of CPZ since diminution of plasma drug levels has been shown for L-dopa, chlorpromazine, sulfa drugs, and phenylbutazone in animals and man treated concomitantly with anticholinergics, which also diminish gastric motility.

摘要

最近一项研究表明，同时服用锂盐的患者氯丙嗪（CPZ）血浆水平较低（58 - 70 ng/ml），尽管他们摄入的氯丙嗪剂量（400 - 1000毫克）通常会使血浆水平达到100 - 300 ng/ml或更高。我们在大鼠中研究了这种锂 - 氯丙嗪相互作用。口服剂量（5微居里）的[14C]氯丙嗪（CPZ）后，锂处理的大鼠血浆和脑内水平显著降低（p < 0.005），而胃内残留剂量百分比（24 - 30%）显著高于（p < 0.001）匹配的对照组。通过[14C]聚乙二醇测量胃排空，结果显示口服和腹腔注射锂可显著抑制胃排空。锂对胃排空的这种抑制作用可能是CPZ血浆水平降低的主要原因，因为在同时接受抗胆碱能药物治疗的动物和人类中，左旋多巴、氯丙嗪、磺胺类药物和保泰松的血浆药物水平也会降低，而抗胆碱能药物同样会减弱胃动力。